At-Home Diagnostics: Inito Secures $29 Million in Series B Funding

At-home diagnostics firm Inito has successfully raised $29 million in a Series B funding round, led by Bertelsmann India Investments, with contributions from existing investor Fireside Ventures. The total equity funding for the company now reaches $45 million. Previously, Inito secured $6 million in a Series A round led by Fireside Ventures in November 2023.

This new capital will enable Inito to expand its offerings beyond fertility testing into a wider array of hormone and health diagnostics, leveraging AI-powered antibody engineering.

Inito’s Entry into the Market

Inito made its market debut in 2021 with an at-home fertility device designed to measure four hormone markers, interpreting results through proprietary models. According to the company, the device has handled over 30 million data points worldwide. Following its success in fertility monitoring, Inito is now working on tests for additional biomarkers that pertain to women’s health as well as general health.

Future Directions for Inito

Co-founders Aayush Rai and Varun AV indicated that the forthcoming phase of the business will concentrate on utilising computational protein design to develop synthetic antibodies. This innovative strategy aims to replace traditional antibody development methods, which often depend on animal-derived materials and manual screening processes.

Inito seeks to establish a reliable and consistent basis for at-home diagnostic tests that have traditionally necessitated clinical infrastructure. The brand is developing products related to testosterone, thyroid levels, vitamins, and other analytes to address a broader health-monitoring spectrum.

With teams located in Bengaluru, Dubai, and London, Inito holds over 20 patents associated with its testing platform.